Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
This NMA shows that pirtobrutinib has better PFS outcomes than ibrutinib. While PFS outcomes suggest that pirtobrutinib is comparable to second-generation covalent BTKi monotherapies, uncertainty exists in the interpretation of the treatment effect, as evidenced by wide credible intervals. These findings suggest the value of pirtobrutinib as a future treatment option for patients in the first-line setting.
Authors
- Lisa M. Hess (ORCID: https://orcid.org/0000-0003-3631-3941)
- Naleen Raj Bhandari (ORCID: https://orcid.org/0000-0002-4452-8021)
- Peita Louise Graham-Clarke
- Matthew Steven Davids (ORCID: https://orcid.org/0000-0003-4529-2003)
- Sarang Abhyankar
- Peter Maguire (ORCID: https://orcid.org/0000-0002-1051-3921)
- Kaisa-Leena Taipale (ORCID: https://orcid.org/0000-0003-1741-6056)
- Katherine B. Winfree (ORCID: https://orcid.org/0000-0003-2088-1004)
- Ehsan Masoudi
- Min-Hua Jen
- Toby A. Eyre
- Marsha Tracey
Institutions
- Eli Lilly (United States) (US)
- Eli Lilly (United Kingdom) (GB)
- Eli Lilly (Ireland) (IE)
- Eli Lilly (Germany) (DE)
- Dana-Farber Cancer Institute (US)
- Oxford University Hospitals NHS Trust (GB)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3390/cancers18040660
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company